Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

All articles

Showing 13–24 of 411 articles

  • Check methods and identity

    What newer muscle imaging adds to the ACE-083 story

    ACE-083 is a larger engineered fusion protein made from modified follistatin and the Fc region of a human antibody. It was designed to capture signals that restrict muscle growth near the muscle under study.

    ACE-0832 sources (2022, 2026)

  • Interpret the evidence

    Why bigger muscles did not settle the FSHD trial

    ACE-083 is an investigational fusion protein based on follistatin. It was engineered to sequester myostatin, activins and other signals around a targeted muscle.

    ACE-0831 source (2022)

  • Explore study findings

    What the Charcot-Marie-Tooth trial learned from the ankle

    ACE-083 is a larger engineered protein that combines a form of follistatin with an antibody Fc region. It was investigated for local muscle growth.

    ACE-0831 source (2022)

  • Explore study findings

    What healthy volunteers revealed about a local effect

    ACE-083 is a larger follistatin-based fusion protein developed to trap signals in the tissue where it was placed. Its 2018 first-in-human study asked how healthy volunteers tolerated it and whether a selected muscle changed in volume.

    ACE-0832 sources (2018, 2022)

  • Understand the science

    How the fusion protein was designed to stay local

    ACE-083 is an engineered fusion protein containing human FST291, a form of follistatin, joined to the Fc region of human IgG2. An older 2019 study looked at two kinds of binding that mattered for the design.

    ACE-0831 source (2019)

  • Explore study findings

    What mouse models could reveal about contraction

    ACE-083 is a larger engineered follistatin fusion protein built to capture several growth-regulating proteins locally. A 2019 animal study asked whether muscle enlargement after ACE-083 came with a change in the force that the same muscle could produce.

    ACE-0832 sources (2019, 2022)

  • Explore study findings

    What a 2026 study revealed about adipotide’s target

    Adipotide is an experimental construct with two linked peptide segments. One was designed to recognize a form of a protein called prohibitin-1 at the surface of blood vessels that supply white fat. The other can trigger programmed cell death after entering a cell.

    Adipotide2 sources (2011, 2026)

  • Understand the science

    How scientists found a peptide that homes to fat blood vessels

    Adipotide is an experimental peptide-based construct built around that principle. Its discovery started with a question about location. Could researchers find a sequence that would collect preferentially in the small blood vessels that serve white fat?

    Adipotide1 source (2004)

  • Check methods and identity

    What imaging revealed in the adipotide monkey experiment

    Adipotide is an experimental peptide construct designed to reach the blood vessels that supply white fat and trigger the death of some of the cells lining those vessels. An older primate study asked whether changes on the scale corresponded to changes in the amount of fat tissue.

    Adipotide1 source (2011)

  • Explore study findings

    Why the adipotide kidney findings mattered

    Adipotide is an investigational two-part peptide construct designed to reach white fat blood vessels and trigger programmed cell death there. The older direct studies illustrate why a report on where a peptide is intended to act belongs alongside observations of which organs actually respond.

    Adipotide2 sources (2010–2019)

  • Explore study findings

    What changed when researchers put the peptide cargo in a nanoparticle

    Adipotide connects a fat-vessel-targeting segment directly to a segment that triggers cell death. An older mouse experiment compared this linked design with a delivery particle carrying a similar payload and displaying the targeting peptide on its surface.

    Adipotide1 source (2013)

  • Understand the science

    How to read adipotide’s terminated first-in-human trial

    Adipotide, studied under the name prohibitin targeting peptide 1, pairs a fat blood vessel recognition sequence with a cell-killing segment. Its older ClinicalTrials.gov record provides a concrete example of what a registered study can tell a reader when results are unavailable.

    Adipotide2 sources (2010–2019)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)